INTERDIS APPROACH TO PHARM II
Duke University · NC · PHARM535
INTERDIS APPROACH TO PHARM II is a subject at Duke University, NC in [object Object]. It covers topics like clinical-pharmacy, drug-design, pharmacology, pharmacy. It is part of 2 degrees. The information below is compiled from public course material — approximate, not official.
Duke University
PHARM535
4.00
[object Object]
Topics covered
Degrees that include INTERDIS APPROACH TO PHARM II
Frequently asked questions
What is INTERDIS APPROACH TO PHARM II about?
INTERDIS APPROACH TO PHARM II covers topics like clinical-pharmacy, drug-design, pharmacology, pharmacy.
Which degrees include INTERDIS APPROACH TO PHARM II?
INTERDIS APPROACH TO PHARM II is part of 2 degrees, including Pharmacology-PHD, Residency in Pharm.Pract.-Cert.
How many credit points is INTERDIS APPROACH TO PHARM II?
INTERDIS APPROACH TO PHARM II at Duke University is typically around 4.00 credit points. Approximate — confirm with the university.
Where is INTERDIS APPROACH TO PHARM II taught?
INTERDIS APPROACH TO PHARM II is taught at Duke University, NC.
Studying INTERDIS APPROACH TO PHARM II?
Peernovo helps students research, choose and thrive at university — across Australia, the US, the UK and Canada — powered by our AI backbone:
- Explore & compare degrees — across universities and countries with honest, specific information.
- "What Can I Be?" career guidance — an AI pathway councillor that maps degrees to careers.
- See who's studying — your degree at your university — find classmates and study groups.
- AI Task Coach — a Socratic study companion that plans your work around your life.
- Honours & Thesis Research Coach — structure and move your research project forward.
- Smart study planner, exam prep and a daily digest — to keep you on track.
Sources: Duke University public course catalogue. Information is compiled and summarised — not copied verbatim — and is approximate; always confirm with the original source.
Something not right on this page, or want it changed? Let us know and we'll review it.